NCT02092909View on ClinicalTrials.gov

Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

April 30, 2017

Study Completion Date

November 30, 2017

Conditions
Waldenstrom's Macroglobulinemia
Interventions
DRUG

IMO-8400

IMO-8400 at escalating dose levels by subcutaneous injection

Trial Locations (10)

10065

Memorial Sloan-Kettering Cancer Center, New York

30322

Emory Winship Cancer Institute, Atlanta

32224

Mayo Clinic Jacksonville, Jacksonville

47905

Horizon BioAdvance, Lafayette

55902

Mayo Clinic, Rochester

72758

Cancer Centers of Excellence, Fayetteville

77030

MD Anderson Cancer Center, Houston

90404

UCLA, Los Angeles

98109

Seattle Cancer Care Alliance, Seattle

07601

Hackensack University, Hackensack

Sponsors
All Listed Sponsors
lead

Idera Pharmaceuticals, Inc.

INDUSTRY

NCT02092909 - Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia | Biotech Hunter | Biotech Hunter